Considering that mutated EGFR is used as a prognostic indicator, better prognosis may be associated with the presence of EML4-ALK fusions in NSCLC, suggesting that EML4-ALK may represent an effective prognostic factor, similar to EGFR. The gene discussed is ALK; the disease is non-small cell lung carcinoma.